BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Celeris Therapeutics

Celeris Therapeutics logo

Founded
2020
Publications
2

Technologies

AI Companies (Drug Discovery) Protein Degraders Startups

Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (Celeris One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices.


Posts Mentioning This Company

7 Companies Using AI to Design Protein Degraders

  
Our cells function in the continuous mode of producing and degrading proteins, keeping the balance between these two processes to maintain a healthy cellular function. However, sometimes the produced proteins might be defective, accumulating and causing pathological effects. This is one of the examples when hijacking the naturally occurring process …

Protein Degraders Take Industry By Storm

  
Proteins are essential components of living matter — they function as building blocks for cells and tissues, as well as participate in signaling and practically all biochemical activities.  However, each protein operates correctly only for a limited time and is eliminated by molecular machinery after it has reached its “functional …

Pharmaceutical AI in 2021: Key Developments So Far

  
Table of Contents:   Introduction Artificial intelligence (AI) in drug discovery yields breakthroughs The abundance of venture capital, major funding rounds IPOs of AI Pharma Companies in 2021 New AI-driven biotech startups founded in 2020 Notable AI-focused collaborations involving “big pharma” players AI adoption by the contract research organizations (CROs)  …
SHARE